ES2146552B1 - Peptidos inhibidores de tgf/31 - Google Patents

Peptidos inhibidores de tgf/31

Info

Publication number
ES2146552B1
ES2146552B1 ES009802465A ES9802465A ES2146552B1 ES 2146552 B1 ES2146552 B1 ES 2146552B1 ES 009802465 A ES009802465 A ES 009802465A ES 9802465 A ES9802465 A ES 9802465A ES 2146552 B1 ES2146552 B1 ES 2146552B1
Authority
ES
Spain
Prior art keywords
tgf
manufacture
inhibiting peptides
peptides
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009802465A
Other languages
English (en)
Other versions
ES2146552A1 (es
Inventor
Saenz Ignacio Jose Ezquerro
Sagastibelza Juan Jose Lasarte
Valtuena Jesus Prieto
Cuesta Francisco Borras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES009802465A priority Critical patent/ES2146552B1/es
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to US09/831,253 priority patent/US7057013B1/en
Priority to CNB99813614XA priority patent/CN1203091C/zh
Priority to ES99957342T priority patent/ES2262349T3/es
Priority to DK99957342T priority patent/DK1132403T3/da
Priority to SI9930897T priority patent/SI1132403T1/sl
Priority to AU15077/00A priority patent/AU767498B2/en
Priority to AT99957342T priority patent/ATE322505T1/de
Priority to DE69930763T priority patent/DE69930763T2/de
Priority to PCT/ES1999/000375 priority patent/WO2000031135A1/es
Priority to EP99957342A priority patent/EP1132403B1/en
Priority to RU2001117230/04A priority patent/RU2232771C2/ru
Priority to JP2000583961A priority patent/JP3836677B2/ja
Priority to BRPI9915604-0A priority patent/BR9915604B1/pt
Priority to PT99957342T priority patent/PT1132403E/pt
Priority to CA2352537A priority patent/CA2352537C/en
Publication of ES2146552A1 publication Critical patent/ES2146552A1/es
Application granted granted Critical
Publication of ES2146552B1 publication Critical patent/ES2146552B1/es
Priority to JP2006107967A priority patent/JP4002287B2/ja
Priority to US11/401,744 priority patent/US7528226B2/en
Priority to CY20061100805T priority patent/CY1105616T1/el
Priority to JP2007037713A priority patent/JP4068654B2/ja
Priority to JP2007259167A priority patent/JP4237807B2/ja
Priority to JP2008269650A priority patent/JP4272255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos sintéticos antagonistas, obtenidos de TGF{b 1 o de sus receptores en el organismo, que pueden ser utilizados en la fabricación, tanto por sí solos como las secuencias génicas que los codifican y los sistemas recombinantes que los expresen, en la fabricación de composiciones útiles para el tratamiento de enfermedades hepáticas y más concretamente en casos de fibrosis. Dichas composiciones pueden incluir opcionalmente mimotopos de dichos péptidos activos.
ES009802465A 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31 Expired - Fee Related ES2146552B1 (es)

Priority Applications (22)

Application Number Priority Date Filing Date Title
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31
BRPI9915604-0A BR9915604B1 (pt) 1998-11-24 1999-11-23 peptÍdios antagonistas de inibidores de tgf-beta1 e seu uso.
ES99957342T ES2262349T3 (es) 1998-11-24 1999-11-23 Peptidos inhibidorers de tgf beta 1.
DK99957342T DK1132403T3 (da) 1998-11-24 1999-11-23 TGF G Beta1-inhibitorpeptider
SI9930897T SI1132403T1 (sl) 1998-11-24 1999-11-23 Peptidi inhibitorji tgf-g beta 1
AU15077/00A AU767498B2 (en) 1998-11-24 1999-11-23 TGFbeta1 inhibitor peptides
AT99957342T ATE322505T1 (de) 1998-11-24 1999-11-23 Tgf-g beta inhibitor-peptide
CNB99813614XA CN1203091C (zh) 1998-11-24 1999-11-23 TGFβ1－抑制肽
PCT/ES1999/000375 WO2000031135A1 (es) 1998-11-24 1999-11-23 PEPTIDOS INHIBIDORES DE TGFβ1
EP99957342A EP1132403B1 (en) 1998-11-24 1999-11-23 Tgf g beta1 inhibitor peptides
RU2001117230/04A RU2232771C2 (ru) 1998-11-24 1999-11-23 Пептиды, ингибирующие трансформирующий фактор роста tgfбета1
JP2000583961A JP3836677B2 (ja) 1998-11-24 1999-11-23 ＴＧＦβ１−インヒビターペプチド
US09/831,253 US7057013B1 (en) 1998-11-24 1999-11-23 TGFβ1 inhibitor peptides
PT99957342T PT1132403E (pt) 1998-11-24 1999-11-23 Peptidos inibidores de tgf g beta1
CA2352537A CA2352537C (en) 1998-11-24 1999-11-23 Tgf.beta.1-inhibitor peptides
DE69930763T DE69930763T2 (de) 1998-11-24 1999-11-23 Tgf-g beta inhibitor-peptide
JP2006107967A JP4002287B2 (ja) 1998-11-24 2006-04-10 ＴＧＦβ１−インヒビターペプチド
US11/401,744 US7528226B2 (en) 1998-11-24 2006-04-11 TGFβ1-inhibitor peptides
CY20061100805T CY1105616T1 (el) 1998-11-24 2006-06-16 ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
JP2007037713A JP4068654B2 (ja) 1998-11-24 2007-02-19 ＴＧＦβ１−インヒビターペプチド
JP2007259167A JP4237807B2 (ja) 1998-11-24 2007-10-02 ＴＧＦβ１−インヒビターペプチド
JP2008269650A JP4272255B2 (ja) 1998-11-24 2008-10-20 ＴＧＦβ１−インヒビターペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31

Publications (2)

Publication Number Publication Date
ES2146552A1 ES2146552A1 (es) 2000-08-01
ES2146552B1 true ES2146552B1 (es) 2001-04-16

Family

ID=8305903

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009802465A Expired - Fee Related ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31
ES99957342T Expired - Lifetime ES2262349T3 (es) 1998-11-24 1999-11-23 Peptidos inhibidorers de tgf beta 1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99957342T Expired - Lifetime ES2262349T3 (es) 1998-11-24 1999-11-23 Peptidos inhibidorers de tgf beta 1.

Country Status (16)

Country Link
US (2) US7057013B1 (es)
EP (1) EP1132403B1 (es)
JP (5) JP3836677B2 (es)
CN (1) CN1203091C (es)
AT (1) ATE322505T1 (es)
AU (1) AU767498B2 (es)
BR (1) BR9915604B1 (es)
CA (1) CA2352537C (es)
CY (1) CY1105616T1 (es)
DE (1) DE69930763T2 (es)
DK (1) DK1132403T3 (es)
ES (2) ES2146552B1 (es)
PT (1) PT1132403E (es)
RU (1) RU2232771C2 (es)
SI (1) SI1132403T1 (es)
WO (1) WO2000031135A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
JP2002087938A (ja) * 2000-09-11 2002-03-27 Shiseido Co Ltd 養毛剤及びそのスクリーニング方法
EP1534737A4 (en) * 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDANTAGONISTS OF MEMBERS OF THE TGF BETA FAMILY AND THEIR THERAPEUTIC APPLICATION
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
AU2005337776B2 (en) * 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
RU2420307C2 (ru) * 2005-10-24 2011-06-10 Проекто Де Биомедисина Сима, С.Л. ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
JP4630914B2 (ja) 2008-04-14 2011-02-09 株式会社日本ハイポックス 肝線維化抑制剤
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物
EP2341913B1 (en) 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
WO2010089443A2 (es) 2009-02-05 2010-08-12 Digna Biotech,S.L. FORMULACIONES FARMACÉUTICAS DE PÉPTIDOS INHIBIDORES DE TGF- β1
ES2347627B1 (es) 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
WO2011054994A1 (es) 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Sistemas de expresión regulada
JP2013520173A (ja) * 2010-02-18 2013-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαｖβ８中和抗体
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
EP2754719B1 (en) 2011-09-05 2018-08-29 Pola Pharma Inc. Method of using etfb as biomarker for identifying the growth state of fibroblasts
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
EP3702443B1 (en) 2013-03-14 2022-01-19 The Brigham and Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
BR112016002015A2 (pt) 2013-07-30 2017-08-01 Kyoto Prefectural Public Univ Corp medicamentos terapêuticos para ecm em endotélio da córnea
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP3804760A1 (en) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3071215B1 (en) 2013-11-21 2020-01-08 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
CN114470207B (zh) 2014-08-01 2023-09-19 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
CA2959404A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
KR20250093593A (ko) 2015-08-04 2025-06-24 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
KR101841748B1 (ko) * 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101791526B1 (ko) 2016-02-18 2017-11-01 (주)케어젠 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2018125746A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
JP7267664B2 (ja) 2017-05-04 2023-05-02 アクセルロン ファーマ インコーポレイテッド Ｔｇｆベータ受容体ｉｉ型融合タンパク質およびその使用
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
CN109432431B (zh) 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
JP2022515652A (ja) 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
KR102265432B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
US20240067686A1 (en) * 2020-12-23 2024-02-29 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-ß SIGNALING AND USE THEREOF
WO2023249439A1 (ko) * 2022-06-22 2023-12-28 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
JPH06500574A (ja) * 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy

Also Published As

Publication number Publication date
US7057013B1 (en) 2006-06-06
JP3836677B2 (ja) 2006-10-25
BR9915604A (pt) 2001-08-07
EP1132403B1 (en) 2006-04-05
ES2146552A1 (es) 2000-08-01
CN1203091C (zh) 2005-05-25
ES2262349T3 (es) 2006-11-16
JP2009040796A (ja) 2009-02-26
JP4237807B2 (ja) 2009-03-11
JP4002287B2 (ja) 2007-10-31
JP4068654B2 (ja) 2008-03-26
CN1328569A (zh) 2001-12-26
PT1132403E (pt) 2006-07-31
DK1132403T3 (da) 2006-08-14
AU767498B2 (en) 2003-11-13
JP2008056685A (ja) 2008-03-13
JP4272255B2 (ja) 2009-06-03
US20070014767A1 (en) 2007-01-18
AU1507700A (en) 2000-06-13
CY1105616T1 (el) 2010-07-28
CA2352537A1 (en) 2000-06-02
US7528226B2 (en) 2009-05-05
WO2000031135A1 (es) 2000-06-02
DE69930763T2 (de) 2006-11-30
EP1132403A1 (en) 2001-09-12
CA2352537C (en) 2011-11-15
SI1132403T1 (sl) 2006-08-31
RU2232771C2 (ru) 2004-07-20
JP2006241166A (ja) 2006-09-14
DE69930763D1 (en) 2006-05-18
BR9915604B1 (pt) 2011-07-26
JP2002530431A (ja) 2002-09-17
JP2007186519A (ja) 2007-07-26
ATE322505T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
ES2146552B1 (es) Peptidos inhibidores de tgf/31
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
ES2190803T3 (es) Iminas ciclicas como pesticidas.
ES2183937T3 (es) Inhibidores de la adhesion celular.
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
SE9802729D0 (sv) Novel Compounds
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
AR016981A2 (es) Polipeptidos sinteticos
GT199900129A (es) Formulaciones liquidas de pirimetanilo y metodos para su preparacion.
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
NO20073914L (no) Biologisk aktive peptider
ES2192610T3 (es) Aminouracilos substituidos.
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
SV2002000418A (es) Inhibidor del intercambiador de socio-hidrogeno de tipo 1 ref. pc1086aado/bb
MX9702659A (es) Pirroliltetrahidrobenzoquinoxalindionas, su preparacion y uso.
BR9915537A (pt) Gene prv-1 e sua utilização
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
ES2058770T3 (es) Nitroanilidas de acidos 1-metoxi-pirimidinil-1h-1,2,4-triazol-3-sulfonicos, procedimiento para su preparacion y su utilizacion como agentes con efecto herbicida.
ES2150682T3 (es) Sulfonilamino(tio)carboniltriazolinonas con heterocicliloxi-substituyentes.
DE69418050D1 (de) Antivirale analoge von difluorostaton
ECSP972266A (es) Terapia de combinacion para el tratamiento de psicosis
MX9706024A (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
TR199701646A2 (xx) Vitronektin-reseptör antagonistleri,üretimleri ve kullanımları

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000801

Kind code of ref document: A1

Effective date: 20000801

FD1A Patent lapsed

Effective date: 20100315